The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Ipsen
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Agios; Array BioPharma (I); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boston Scientific; Bristol-Myers Squibb (I); CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; Delcath Systems; Eisai; EMD Serono (I); Gilead Sciences (I); Halozyme (I); IntegraGen; Ipsen; Janssen (I); Medimmune; Merck Serono; Merrimack; Merrimack (I); Momenta Pharmaceuticals (I); New B Innovation; Newlink Genetics (I); Onxeo; Opsona Therapeutics (I); Pfizer (I); Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; VAXIMM (I); Vicus Therapeutics; Vicus Therapeutics (I); Westhaven
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Chugai Pharma (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris
 
Tim Meyer
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Ann-Lii Cheng
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Serono; Novartis; Ono Pharmaceutical; ONXEO
Speakers' Bureau - Novartis
Research Funding - Sanofi
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Merrimack; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CytomX Therapeutics
Speakers' Bureau - Merrimack
 
Lorenza Rimassa
Consulting or Advisory Role - ArQule; Bayer; Italfarmaco; Lilly; Sanofi; Sirtex Medical
Travel, Accommodations, Expenses - ArQule
Other Relationship - Amgen
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Irfan Cicin
No Relationships to Disclose
 
Philippe Merle
No Relationships to Disclose
 
Joong-Won Park
Honoraria - Bayer; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Ono Pharmaceutical
 
Jean-Frédéric Blanc
Honoraria - Baxalta/Shire; Bayer Schering Pharma; Gilead Sciences
Consulting or Advisory Role - Baxalta/Shire; Bristol-Myers Squibb; Novartis; Onxeo
Travel, Accommodations, Expenses - Bayer Schering Pharma
 
Luigi Bolondi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Lilly; Sirtex Medical
Speakers' Bureau - Bayer; Bracco Diagnostics; Bristol-Myers Squibb; Lilly; Sirtex Medical
Research Funding - Bayer; Bristol-Myers Squibb; Daiichi Sankyo
Travel, Accommodations, Expenses - Bayer; Bracco Diagnostics
 
Heinz Josef Klümpen
No Relationships to Disclose
 
Stephen Lam Chan
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca/MedImmune; MSD Oncology; Novartis
Research Funding - Novartis; Sirtex Medical
 
Vincenzo Dadduzio
No Relationships to Disclose
 
Colin Hessel
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Anne E. Borgman-Hagey
Employment - Exelixis
 
Gisela Schwab
Employment - Exelixis
Leadership - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Tekmira (Inst)